Dealmaking Roundup March 2007
Summary of recent device mergers and acquisitions, alliances, and financings.
You may also be interested in...
Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.